Research And Markets Research And Markets
0 CHECKOUT

Myelofibrosis - Pipeline Review, H2 2015

  • ID: 3455174
  • September 2015
  • 189 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • CTI BioPharma Corp.
  • Gilead Sciences, Inc.
  • Italfarmaco S.p.A.
  • Nippon Shinyaku Co., Ltd.
  • Pfizer Inc.
  • MORE

Myelofibrosis - Pipeline Review, H2 2015

Summary

The report ‘Myelofibrosis - Pipeline Review, H2 2015’, provides an overview of the Myelofibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • CTI BioPharma Corp.
  • Gilead Sciences, Inc.
  • Italfarmaco S.p.A.
  • Nippon Shinyaku Co., Ltd.
  • Pfizer Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Myelofibrosis Overview

Therapeutics Development

Pipeline Products for Myelofibrosis - Overview

Pipeline Products for Myelofibrosis - Comparative Analysis

Myelofibrosis - Therapeutics under Development by Companies

Myelofibrosis - Therapeutics under Investigation by Universities/Institutes

Myelofibrosis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Myelofibrosis - Products under Development by Companies

Myelofibrosis - Products under Investigation by Universities/Institutes

Myelofibrosis - Companies Involved in Therapeutics Development

Acceleron Pharma, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

CTI BioPharma Corp.

Galena Biopharma, Inc.

Gilead Sciences, Inc.

Incyte Corporation

Italfarmaco S.p.A.

Johnson & Johnson

JW Pharmaceutical Corporation

KaloBios Pharmaceuticals, Inc.

Nippon Shinyaku Co., Ltd.

Novartis AG

Onconova Therapeutics, Inc.

Pfizer Inc.

PharmaEssentia Corporation

Promedior, Inc.

Stemline Therapeutics, Inc.

Threshold Pharmaceuticals, Inc.

Myelofibrosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

anagrelide hydrochloride CR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BMS-911543 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

buparlisib hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CWP-291 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

erismodegib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

evofosfamide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

glasdegib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Hu8F4 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

idelalisib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

imetelstat sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INCB-39110 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KB-004 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LCL-161 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

momelotinib dihydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NS-018 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pacritinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pixantrone dimaleate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pomalidomide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PRM-151 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rigosertib sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ropeginterferon ALFA-2B - Drug Profile

Product Description

Mechanism of Action

R&D Progress

simtuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SL-401 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sotatercept - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Myelofibrosis - Recent Pipeline Updates

Myelofibrosis - Dormant Projects

Myelofibrosis - Discontinued Products

Myelofibrosis - Product Development Milestones

Featured News & Press Releases

Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis

Jun 12, 2015: Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis

Jun 12, 2015: Promedior Presents Additional Positive Phase 2 Data for PRM-151 in Myelofibrosis at EHA Annual Meeting

Jun 10, 2015: CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA

Jun 04, 2015: Promedior Announces Presentation of Additional Positive Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of the European Hematology Association

May 30, 2015: Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015

May 14, 2015: Baxter BioScience to Present New Data at ASCO On Pacritinib from Expanding Oncology Pipeline Designed to Address Unmet Needs in Challenging Cancers

Apr 27, 2015: Geron to Present at the Bank of America Merrill Lynch Healthcare Conference

Apr 22, 2015: CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO

Mar 16, 2015: CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Myelofibrosis, H2 2015

Number of Products under Development for Myelofibrosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Myelofibrosis - Pipeline by Acceleron Pharma, Inc., H2 2015

Myelofibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2015

Myelofibrosis - Pipeline by Celgene Corporation, H2 2015

Myelofibrosis - Pipeline by CTI BioPharma Corp., H2 2015

Myelofibrosis - Pipeline by Galena Biopharma, Inc., H2 2015

Myelofibrosis - Pipeline by Gilead Sciences, Inc., H2 2015

Myelofibrosis - Pipeline by Incyte Corporation, H2 2015

Myelofibrosis - Pipeline by Italfarmaco S.p.A., H2 2015

Myelofibrosis - Pipeline by Johnson & Johnson, H2 2015

Myelofibrosis - Pipeline by JW Pharmaceutical Corporation, H2 2015

Myelofibrosis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015

Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015

Myelofibrosis - Pipeline by Novartis AG, H2 2015

Myelofibrosis - Pipeline by Onconova Therapeutics, Inc., H2 2015

Myelofibrosis - Pipeline by Pfizer Inc., H2 2015

Myelofibrosis - Pipeline by PharmaEssentia Corporation, H2 2015

Myelofibrosis - Pipeline by Promedior, Inc., H2 2015

Myelofibrosis - Pipeline by Stemline Therapeutics, Inc., H2 2015

Myelofibrosis - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Myelofibrosis Therapeutics - Recent Pipeline Updates, H2 2015

Myelofibrosis - Dormant Projects, H2 2015

Myelofibrosis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Myelofibrosis, H2 2015

Number of Products under Development for Myelofibrosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Acceleron Pharma, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
CTI BioPharma Corp.
Galena Biopharma, Inc.
Gilead Sciences, Inc.
Incyte Corporation
Italfarmaco S.p.A.
Johnson & Johnson
JW Pharmaceutical Corporation
KaloBios Pharmaceuticals, Inc.
Nippon Shinyaku Co., Ltd.
Novartis AG
Onconova Therapeutics, Inc.
Pfizer Inc.
PharmaEssentia Corporation
Promedior, Inc.
Stemline Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db